Transforming growth factor-β signaling in systemic sclerosis

Abstract

Systemic sclerosis (SSc) is a complex, multiorgan autoimmune disease of unknown etiology. Manifestation of the disease results from an interaction of three key pathologic features including irregularities of the antigen-specific immune system and the non-specific immune system, resulting in autoantibody production, vascular endothelial activation of small blood vessels, and tissue fibrosis as a result of fibroblast dysfunction. Given the heterogeneity of clinical presentation of the disease, a lack of universal models has impeded adequate testing of potential therapies for SSc. Regardless, recent research has elucidated the roles of various ubiquitous molecular mechanisms that contribute to the clinical manifestation of the disease. Transforming growth factor β (TGF-β) has been identified as a regulator of pathological fibrogenesis in SSc. Various processes, including cell growth, apoptosis, cell differentiation, and extracellular matrix synthesis are regulated by TGF-β, a type of cytokine secreted by macrophages and many other cell types. Understanding the essential role TGF-β pathways play in the pathology of systemic sclerosis could provide a potential outlet for treatment and a better understanding of this severe disease.

Keywords

systemic sclerosis / transforming growth factor-β / mechanism / therapeutics

References

[1] Bernatsky S, Joseph L, Pineau CA, Scleroderma prevalence: demographic variations in a population-based sample[J]. Arthritis Rheum, 2009, 61(3): 400–404

[2] Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis[J]. Annu Rev Pathol, 2011, 6: 509–537

[3] Denton CP. Advances in pathogenesis and treatment of systemic sclerosis[J]. Clin Med (Lond), 2016, 16(1): 55–60

[4] Koenig M, Joyal F, Fritzler MJ, Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis[J]. Arthritis Rheum, 2008, 58(12): 3902–3912

[5] Pattanaik D, Brown M, Postlethwaite BC, Pathogenesis of systemic sclerosis[J]. Front Immunol, 2015, 6: 272

[6] van den Hoogen F, Khanna D, Fransen J, 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2013, 65(11): 2737–2747

[7] Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement[J]. Curr Opin Rheumatol, 2014, 26(6): 646–652

[8] Xu D, Hou Y, Zheng Y, The 2013 American college of rheumatology/european league against rheumatism classification criteria for systemic sclerosis could classify systemic sclerosis patients at earlier stage: data from a Chinese EUSTAR center[J]. PLoS One, 2016, 11(11): e0166629

[9] Asano Y. Recent advances in animal models of systemic sclerosis[J]. J Dermatol, 2016, 43(1): 19–28

[10] Ghosh AK, Bhattacharyya S, Lafyatis R, p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis[J]. J Invest Dermatol, 2013, 133(5): 1302–1310

[11] Sato S. Understanding the pathogenesis and developing new therapy of systemic sclerosis[J]. J Dermatol, 2016, 43(1): 9

[12] Shanmugam VK, Swistowski DR, Saddic N, Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis[J]. Clin Rheumatol, 2011, 30(10): 1363–1368

[13] Sato S, Fujimoto M, Hasegawa M, Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells[J]. Arthritis Rheum, 2004, 50(6): 1918–1927

[14] Yoshizaki A, Sato S. Abnormal B lymphocyte activation and function in systemic sclerosis[J]. Ann Dermatol, 2015, 27(1): 1–9

[15] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol, 2008, 8(12): 958–969

[16] Schultze JL, Schmidt SV. Molecular features of macrophage activation[J]. Semin Immunol, 2015, 27(6): 416–423

[17] Raes G, Beschin A, Ghassabeh GH, Alternatively activated macrophages in protozoan infections[J]. Curr Opin Immunol, 2007, 19(4): 454–459

[18] Gong D, Shi W, Yi SJ, TGFβ signaling plays a critical role in promoting alternative macrophage activation[J]. BMC Immunol, 2012, 13: 31

[19] Duffy L, O’Reilly SC. Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments[J]. Immunotargets Ther, 2016, 5: 69–80

[20] Lester SN, Li K. Toll-like receptors in antiviral innate immunity[J]. J Mol Biol, 2014, 426(6): 1246–1264

[21] Bhattacharyya S, Kelley K, Melichian DS, Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma[J]. Am J Pathol, 2013, 182(1): 192– 205

[22] Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation[J]? Immunol Rev, 2004, 202: 250–265

[23] Dowson C, Simpson N, Duffy L, Innate immunity in systemic sclerosis[J]. Curr Rheumatol Rep, 2017, 19(1): 2

[24] Takeda K, Akira S. Toll-like receptors in innate immunity[J]. Int Immunol, 2005, 17(1): 1–14

[25] Wei J, Bhattacharyya S, Tourtellotte WG, Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy[J]. Autoimmun Rev, 2011, 10(5): 267–275

[26] Fullard N, O’Reilly S. Role of innate immune system in systemic sclerosis[J]. Semin Immunopathol, 2015, 37(5): 511–517

[27] Lakota K, Carns M, Podlusky S, Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis[J]. PLoS One, 2015, 10(1): e0110820

[28] Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis[J]. J Dermatol, 2010, 37(1): 11–25

[29] Komai-Koma M, Li D, Wang E, Anti-Toll-like receptor 2 and 4 antibodies suppress inflammatory response in mice[J].Immunology, 2014, 143(3): 354–362

[30] Mayes MD. Systemic Sclerosis[J]. Rheum Dis Clin North Am, 2015, 41(3): xv–xvi

[31] Baron M. Targeted therapy in systemic sclerosis[J]. Rambam Maimonides Med J, 2016, 7(4): e0030

[32] Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis[J]. Nat Rev Rheumatol, 2010, 6(8): 453–460

[33] Aringer M, Erler A. Recent advances in managing systemic sclerosis[J]. F1000Res, 2017, 6: 88

[34] Kumar S, Singh J, Rattan S, Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis[J]. Aliment Pharmacol Ther, 2017, 45(7): 883–898

[35] Liakouli V, Cipriani P, Marrelli A, Angiogenic cytokines and growth factors in systemic sclerosis[J]. Autoimmun Rev, 2011, 10(10): 590–594

[36] Mazzotta C, Manetti M, Rosa I, Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells[J]. Arthritis Res Ther, 2017, 19(1): 27

[37] Nicolosi PA, Tombetti E, Maugeri N, Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis[J]. Stem Cells Int 2016,2016:4636859.

[38] Jarad M, Kuczynski EA, Morrison J, Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro[J]. BMC Cell Biol, 2017, 18(1): 10

[39] Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis[J]. Circ Res, 2008, 102(6): 637–652

[40] Lafyatis R. Transforming growth factor β--at the centre of systemic sclerosis[J]. Nat Rev Rheumatol, 2014, 10(12): 706–719

[41] Shiwen X, Leask A, Abraham DJ, Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma[J]. Eur J Clin Invest, 2009, 39(Suppl 2): 19–26

[42] Kavian N, Batteux F. Macro- and microvascular disease in systemic sclerosis[J]. Vascul Pharmacol, 2015, 71: 16–23

[43] Avouac J, Vallucci M, Smith V, Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis[J]. Arthritis Res Ther, 2013, 15(2): R55

[44] Tsujino K, Reed NI, Atakilit A, Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 312(1): L22–L31

[45] Baraut J, Farge D, Jean-Louis F, Transforming growth factor-β increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis[J]. Arthritis Res Ther, 2015, 17: 196

[46] Ciechomska M, van Laar J, O’Reilly S. Current frontiers in systemic sclerosis pathogenesis[J]. Exp Dermatol, 2015, 24(6): 401–406

[47] Denton CP. Advances in pathogenesis and treatment of systemic sclerosis[J]. Clin Med (Lond), 2015, 15(Suppl 6): s58–s63

[48] Pang N, Zhang F, Ma X, TGF-β/Smad signaling pathway regulates Th17/Treg balance during Echinococcus multilocularis infection[J]. Int Immunopharmacol, 2014, 20(1): 248–257

[49] Yung LM, Nikolic I, Paskin-Flerlage SD, A selective transforming growth factor-β ligand trap attenuates pulmonary hypertension[J]. Am J Respir Crit Care Med, 2016, 194(9): 1140–1151

[50] Graham BB, Chabon J, Gebreab L, Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni[J]. Circulation, 2013, 128(12): 1354–1364

[51] Artlett CM. Animal models of systemic sclerosis: their utility and limitations[J]. Open Access Rheumatol, 2014, 6: 65–81

[52] Varga J. Systemic sclerosis: an update[J]. Bull NYU Hosp Jt Dis, 2008, 66(3): 198–202

[53] Maurer B, Reich N, Juengel A, Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis[J]. Ann Rheum Dis, 2012, 71(8): 1382–1387

[54] Noda S, Asano Y, Nishimura S, Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis[J]. Nat Commun, 2014, 5: 5797

[55] Asano Y, Bujor AM, Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis[J]. J Dermatol Sci, 2010, 59(3): 153–162

[56] Whitfield ML, Finlay DR, Murray JI, Systemic and cell type-specific gene expression patterns in scleroderma skin[J]. Proc Natl Acad Sci U S A, 2003, 100(21): 12319–12324

[57] Asano Y, Sato S. Animal models of scleroderma: current state and recent development[J]. Curr Rheumatol Rep, 2013, 15(12): 382

[58] Ishikawa H, Takeda K, Okamoto A, Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells[J]. J Invest Dermatol, 2009, 129(7): 1688–1695

[59] Liang M, Lv J, Zou L, A modified murine model of systemic sclerosis: bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis[J]. Lab Invest, 2015, 95(3): 342–350

[60] Avouac J, Borderie D, Ekindjian OG, High DNA oxidative damage in systemic sclerosis[J]. J Rheumatol, 2010, 37(12): 2540–2547

[61] Servettaz A, Goulvestre C, Kavian N, Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse[J]. J Immunol, 2009, 182(9): 5855–5864

[62] Yoshizaki A, Yanaba K, Ogawa A, Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling[J]. Arthritis Rheum, 2011, 63(11): 3575–3585

[63] Massagué J. TGFβ signalling in context[J]. Nat Rev Mol Cell Biol, 2012, 13(10): 616–630

[64] Raja J, Denton CP. Cytokines in the immunopathology of systemic sclerosis[J]. Semin Immunopathol, 2015, 37(5): 543–557

[65] Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses[J]. J Cell Biochem, 2007, 102(3): 593–608

[66] Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma)[J]. Front Biosci (Schol Ed), 2009, 1: 226–235

[67] Pang L, Li Q, Wei C, TGF-β1/Smad signaling pathway regulates epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: in vitro and clinical analyses of cell lines and nomadic Kazakh patients from northwest Xinjiang, China[J]. PLoS One, 2014, 9(12): e112300

[68] Pang K, Ryan JF, Baxevanis AD, Evolution of the TGF-β signaling pathway and its potential role in the ctenophore, Mnemiopsis leidyi[J]. PLoS One, 2011, 6(9): e24152

[69] Samarakoon R, Overstreet JM, Higgins SP, TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis[J]. Cell Tissue Res, 2012, 347(1): 117–128

[70] Kavsak P, Rasmussen RK, Causing CG, Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation[J]. Mol Cell, 2000, 6(6): 1365–1375

[71] Zhou B, Zhu H, Luo H, MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1[J]. Biomed Pharmacother, 2017, 87: 412–418

[72] Luo H, Zhu H, Zhou B, MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor g[J]. Mod Rheumatol, 2015, 25(4): 595–602

[73] Zhu H, Luo H, Li Y, MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression[J]. J Clin Immunol, 2013, 33(6): 1100–1109

[74] Zhu H, Li Y, Qu S, MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma[J]. J Clin Immunol, 2012, 32(3): 514–522

[75] Prud’homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations[J]. Lab Invest, 2007, 87(11): 1077–1091

[76] Ihn H, Yamane K, Tamaki K. Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts[J]. J Invest Dermatol, 2005, 125(2): 247–255

[77] Leask A. Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment[J]. Fibrogenesis Tissue Repair, 2010, 3: 8

[78] Zhang YE. Non-Smad pathways in TGF-beta signaling[J]. Cell Res, 2009, 19(1): 128–139

[79] Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion[J]. Cancer Res, 2007, 67(8): 3752–3758

[80] Gu AD, Wang Y, Lin L, Requirements of transcription factor Smad-dependent and-independent TGF-β signaling to control discrete T-cell functions[J]. Proc Natl Acad Sci U S A, 2012, 109(3): 905–910

[81] Huang T, David L, Mendoza V, TGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairs[J].EMBO J, 2011, 30(7): 1263–1276

[82] Landström M. The TAK1-TRAF6 signalling pathway[J]. Int J Biochem Cell Biol, 2010, 42(5): 585–589

[83] Sorrentino A, Thakur N, Grimsby S, The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner[J]. Nat Cell Biol, 2008, 10(10): 1199–1207

[84] Freudlsperger C, Bian Y, Contag Wise S, TGF-β and NF-kB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers[J]. Oncogene, 2013, 32(12): 1549–1559

[85] Yan X, Chen YG. Smad7: not only a regulator, but also a cross-talk mediator of TGF-β signalling[J]. Biochem J, 2011, 434(1): 1–10

[86] Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis[J]. Nat Rev Nephrol, 2016, 12(6): 325–338

[87] Shi-Wen X, Rodríguez-Pascual F, Lamas S, Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors[J]. Mol Cell Biol, 2006, 26(14): 5518–5527

[88] Leask A, Denton CP, Abraham DJ. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma[J]. J Invest Dermatol, 2004, 122(1): 1–6

[89] Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response[J]. FASEB J, 2004, 18(7): 816–827

[90] Shi-Wen X, Chen Y, Denton CP, Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts[J]. Mol Biol Cell, 2004, 15(6): 2707–2719

[91] Rajkumar VS, Howell K, Csiszar K, Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis[J]. Arthritis Res Ther, 2005, 7(5): R1113–R1123

[92] Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder[J]. J Clin Invest, 2007, 117(3): 557–567

[93] Zhang YE. Non-smad signaling pathways of the TGF-β family[J]. Cold Spring Harb Perspect Biolv, 2017, 9(2): a022129

[94] Hasan M, Neumann B, Haupeltshofer S, Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation[J]. Immunol Cell Biol, 2015, 93(7): 662–672

[95] Elisa T, Antonio P, Giuseppe P, Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis[J]. J Immunol Res 2015, 2015: 147616.

[96] Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing[J]. EMBO Rep, 2010, 11(2): 97–105

[97] Weisman MH. Systemic Sclerosis[J]. Rheum Dis Clin North Am, 2015, 41(3): xiii

[98] Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis[J]. Nat Rev Rheumatol, 2009, 5(4): 200–206

[99] Rice LM, Padilla CM, McLaughlin SR, Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients[J]. J Clin Invest, 2015, 125(7): 2795–2807

[100] Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis[J]. Curr Rheumatol Rep, 2006, 8(2): 145–150

[101] Zeisberg EM, Tarnavski O, Zeisberg M, Endothelial-to-mesenchymal transition contributes to cardiac fibrosis[J]. Nat Med, 2007, 13(8): 952–961

[102] Medici D, Potenta S, Kalluri R. Transforming growth factor-β2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling[J]. Biochem J, 2011, 437(3): 515–520

[103] Ghosh AK, Bradham WS, Gleaves LA, Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition[J].Circulation, 2010, 122(12): 1200–1209

[104] Li J, Qu X, Yao J, Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy[J]. Diabetes, 2010, 59(10): 2612–2624

[105] Mu Y, Sundar R, Thakur N, TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer[J]. Nat Commun, 2011, 2: 330

RIGHTS & PERMISSIONS

2017 2017 by the Journal of Biomedical Research. All rights reserved.